Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Mersana Therapeutics, Inc. (MRSN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Mersana Therapeutics Announces Second Quarter 2023 Financial Results"
08/07/2023 SC 13G Venrock Healthcare Capital Partners III, L.P. reports a 8.5% stake in Mersana Therapeutics, Inc.
07/27/2023 SC 13G EcoR1 Capital, LLC reports a 16.9% stake in Mersana Therapeutics, Inc.
07/27/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Ot...
Docs: "Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization"
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MERSANA THERAPEUTICS, INC."
05/09/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/31/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "MERSANA THERAPEUTICS, INC. SECOND AMENDED AND RESTATED BYLAWS SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting . An annual meeting of the stockholders of Mersana Therapeutics, Inc., a Delaware corporation , for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the State of Delaware, on the date and at the hour that the Board of Directors of the Corporation shall each year fix. Unless stated otherwise in the notice of the annual meeting of the stockholders of the Corporation, such annual meeting shall be at the principal office of the Corporation. Section 1.2. Nominations of Directors . Nominations for election to the Board of Directors..."
03/24/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/13/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Mersana Therapeutics Provides Statement About SVB",
"Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial"
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results"
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 4.5% stake in Mersana Therapeutics Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A STATE STREET CORP reports a 5.9% stake in AMENDED FILING MERSANA THERAPEUTICS INC
02/01/2023 8-K Quarterly results
01/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
01/19/2023 SC 13G/A MILLENNIUM MANAGEMENT LLC reports a 3.7% stake in MERSANA THERAPEUTICS, INC.
01/06/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones"
12/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/22/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
11/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SALES AGREEMENT",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
11/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results"
10/06/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy